Xanax XR recalled after discovery that tablets may fail to release medication properly [FOX Business Network]
Viatris Inc. (VTRS)
Company Research
Source: FOX Business Network
A batch of Xanax XR is being recalled nationwide after the manufacturer found it may not release the medication in the body as intended. Viatris, Inc. initiated the voluntary recall for ALPRAZolam extended-release tablets, 3 mg, distributed in 60-count bottles under lot number 8177156 with an expiration date of Feb. 28, 2027, according to the U.S. Food and Drug Administration. Xanax XR is a benzodiazepine used to treat panic disorder and anxiety in adults. The issue was classified as a Class II recall, meaning it may cause temporary or medically reversible health effects but is unlikely to result in serious harm. "Failed dissolution specifications" indicate the tablets may not dissolve and release the medication at the intended rate. Because Xanax XR is designed to release gradually over time, any variation could affect how the drug is delivered in the body — and how well it works. The affected product was distributed nationwide in the United States, though the recall appli
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Theravance Biopharma: A Special Situation With A 50-100% Likely Upside [Seeking Alpha]Seeking Alpha
- Is It Too Late To Consider Viatris (VTRS) After A 94% One-Year Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Xanax from West Virginia-based company recalled nationwide. What you need to know [Los Angeles Times (CA)]Los Angeles Times
- Viatris to Report First Quarter 2026 Financial Results on May 7, 2026PR Newswire
- Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingPR Newswire
VTRS
Earnings
- 2/26/26 - Beat
VTRS
Sec Filings
- 4/16/26 - Form 4
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- VTRS's page on the SEC website